American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

I hope to see many of the exciting agents presented this year become available and affordable for my patients. But when the miracle isn’t happening we have an obligation to talk it out and be candidly compassionate. We need to know when to put the pedal to the metal and when to hit the brake.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

The MEK inhibitor binimetinib resulted in improved progression-free survival and response rates vs dacarbazine in patients with NRAS-mutated metastatic melanoma.

In this video we discuss how palliative care early on in the process of treating patients with cancer led to an improvement in depressive symptoms and quality of life among family caregivers.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.

I am inspired to finally see the increasing role of immuno-oncology agents in the treatment of cancer, and ASCO 2016 was loaded with fascinating updates on this subject.

A combination of the checkpoint inhibitors nivolumab and ipilimumab continues to demonstrate superior clinical activity vs ipilimumab monotherapy in treatment-naive patients with advanced melanoma.

To date, there is still no strong evidence that induction chemotherapy improves outcomes for locally advanced head and neck cancer.

Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

In this interview we discuss the CheckMate 142 trial, which looked at nivolumab and ipilimumab for the treatment of metastatic colorectal cancer.

Alectinib yielded significantly prolonged progression-free survival compared with crizotinib in ALK-positive NSCLC patients, according to results of a Japanese open-label trial.

In this interview we discuss follow-up care and screening for second primary cancers in cancer survivors.

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.

Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.

A novel first-in-class antibody can significantly extend median survival when added to standard chemotherapy for patients with advanced gastric cancer.

As part of our coverage of the annual ASCO conference, we spoke with Dr. Veronika Bachanova on the role of NK cell therapy in hematologic malignancies.

Patients with relapsed small cell lung cancer now have more options according to study results first presented at the 2016 ASCO Annual Meeting, held June 3–7, 2016, in Chicago.

Busulfan/melphalan high-dose chemotherapy consolidation is associated with better survival vs VAI among patients with localized high-risk Ewing sarcoma.

Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.

In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.

Adjuvant temozolomide chemotherapy following radiotherapy improves survival among patients with anaplastic gliomas that do not harbor 1p/19q co-deletions, according to interim results from a phase III trial.

Early palliative care in cancer patients led to an improvement in depressive symptoms and quality of life among family caregivers.

The physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer, according to an analysis to be presented at ASCO.